China May Ease Data Transfer Rules But Regulatory Ambiguity Remains
New Approach To 'Important Data'
China's latest proposed rules governing the overseas transfer of personal data may allow pharma, biotech and digital health companies to avoid regulatory security reviews and formal standard contracts, as well as personal information protection certification, but key definitions of “important data” and “negative list” items remain to be clarified.
You may also be interested in...
As artificial intelligence-aided drug discovery gains momentum, Sanofi appears keen to hop onboard via a recent tie-up with leading Chinese AI company BioMap. But data challenges, a hard-to-define value proposition, concerns over data security and looming regulations are making others hesitant.
Major Chinese biopharma contract services group WuXi Biologics' share price plummeted after it said external factors would contribute to it missing original revenue targets this year in multiple areas.
Although the spread of HIV/AIDS appears to be largely under control in China, increasing infections among the elderly are causing concern due to a range of risk factors, while domestic firms move to expand their drug offerings.